“Romania is a strategic market for the Polpharma Group’s development and a country of significant importance for the future of Central and Eastern Europe,” says Sebastian Szymanek, CEO of the Polpharma Group.
Biofarm brings to Polpharma a solid market position and an outstanding team that has built the company’s success over many years. Our ambition is to support Biofarm’s continued development by combining its local strengths with the experience and capabilities of an international pharmaceutical organization, the official added.
According to the company, the integration of Biofarm marks the beginning of a long-term development phase, during which the Romanian manufacturer will retain its local identity, team, and relationships with partners, while benefiting from the resources and expertise of the Polish group.
Following the completion of the deal, Sebastian Szymanek, CEO of the Polpharma Group, and Tamás Uri, the group’s general manager for Central and Eastern Europe, will join Biofarm’s Board of Directors.
Biofarm, which has been manufacturing medicines continuously since 1921, operates two production facilities in Romania, exports to Europe and Asia, and has a portfolio of more than 200 products.
(English version by Loredana Fratila-Cristescu)